Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

Dr. Essell explains how allogeneic transplantation is incorporated into hematologic malignancy today

Published: 18 December 2017

Recent Videos

video

Ted Okon, MBA, regarding the key issues faced by community oncologists today

Ted Okon, MBA, Executive Director, Community Oncology Alliance, discusses the key issues faced by community oncologists today

video

Ted Okon, MBA, on what COA is doing to help community oncology practices

Ted Okon, MBA, Executive Director, Community Oncology Alliance, elaborates on what COA is doing to help community oncology practices

video

Ted Okon, MBA, considers what can be done to encourage PBM transparency

Ted Okon, MBA, Executive Director, Community Oncology Alliance, tells us what can be done to encourage transparency at PBMs

video

Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM

Nate Brown, Senior Product Marketing Manager, Flatiron Health, on whether practices already in a MIPS track should consider moving to ...

video

Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, speculates on what might influence the adoption of biosimilars by oncologists

video

Mark Fendrick, MD, considers the challenges associated with value-based insurance design

Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, discusses the challenges associated with value-based insurance design when applied to ...

video

Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care

Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, discusses cancer patient advocacy and the ...

video

Robert Rifkin, MD, lists those biosimilars now approved or close to approval

Dr. Rifkin, Medical Director – Biosimilars, McKesson Specialty Health, shares which biosimilars are currently approved or close to approval for ...

video

Mark Fendrick, MD, on designing incentives when dealing with expensive cancer therapies

Dr. Fendrick, Director, Value-Based Insurance Design, University of Michigan, elaborates on whether newer, more expensive cancer therapies impact value-based insurance ...

video

Ray Page, DO, PhD, on what oncology practices should be doing to advocate for their patients

Dr. Page, President & Director of Research, The Center for Cancer & Blood Disorders, offers opinion on what everyday oncology ...

Related Videos

video-image

Ted Okon, MBA, on what COA is doing to help community oncology practices

video-image

Ted Okon, MBA, considers what can be done to encourage PBM transparency

video-image

Ted Okon, MBA, regarding the key issues faced by community oncologists today

video-image

Miriam Atkins, MD, elaborates on what cancer patients can do to advocate for themselves

video-image

Rebecca A. Kirch, JD, explains how CMS & commercial insurers have embraced palliative care

video-image

Michael Diaz, MD, discusses what cancer patients can do to advocate for themselves

video-image

Nate Brown explains why a practice should participate in MIPS

video-image

Robert Rifkin, MD, explains the key features of biosimilars

video-image

Michael Diaz, MD, considers what PBMs can do to help community oncology

video-image

Nate Brown regarding the steps a practice should take to get started on MIPS

video-image

Robert Rifkin, MD, tells us about the regulatory pathway for gaining FDA approval of a biosimilar

video-image

Mark Fendrick, MD, explains the motivation behind value-based insurance design

video-image

Nate Brown speculates on the future of MIPS and oncology practices

video-image

Robert Rifkin, MD, on the impact of extrapolation and interchangeability on biosimilar use

video-image

Mark Fendrick, MD, provides examples of value-based insurance design in oncology care

video-image

Nate Brown offers opinion on whether practices in a MIPS track should consider moving to an APM

video-image

Robert Rifkin, MD, on the hurdles that might prevent adoption of biosimilars by oncologists

video-image

Mark Fendrick, MD, considers the challenges associated with value-based insurance design

video-image

Ray Page, DO, PhD, explains cancer patient advocacy & how it enhances the delivery of cancer care

video-image

Robert Rifkin, MD, lists those biosimilars now approved or close to approval